RxDoctor Payments Data

Leeann Green

Family · Murrieta, CANPI 1013993658

Payments from drug & device makers

$4,179in general payments, 2019–2025

Across 179 payments — averaging $23.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$801
  • Novo Nordisk$791
  • GSK$415
  • Lilly USA, LLC$362
  • AstraZeneca$212
  • Novartis$183
  • plus $1K from 21 others

What the payments were for

  • Food & beverage$4,179100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,179 in reported general payments places this provider in the 90th percentile of 10,634 family providers in California.

See all family providers in California

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban28$29,548
OzempicSemaglutide28$27,620
Trelegy ElliptaFluticasone/Umeclidin/Vilanter20$22,944
RybelsusSemaglutide12$13,468
JardianceEmpagliflozin14$11,513
Wixela InhubFluticasone Propion/Salmeterol14$5,333
Levothyroxine Sodium164$3,257
Lantus SolostarInsulin Glargine,hum.Rec.Anlog20$3,100
PaxlovidNirmatrelvir/Ritonavir13$2,859
Albuterol Sulfate HfaAlbuterol Sulfate76$2,456
Atorvastatin Calcium188$2,269
Rosuvastatin Calcium129$2,043
Losartan Potassium120$1,887
Nano 2nd Gen Pen NeedlePen Needle, Diabetic25$1,651
Metoprolol Succinate68$1,431

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$791$41,08740 claims
PfizerEliquis, Paxlovid$156$32,40741 claims
GSKTrelegy Ellipta$415$22,94420 claims
Boehringer IngelheimJardiance$23$11,51314 claims
AbbVieSynthroid$801$79920 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 10,634 family providers in California.

Other family in Murrieta

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →